News
AMAM
28.00
0.00%
0.00
RPT-BUZZ-PREVIEW: Johnson & Johnson shares rise ahead of quarterly results
Shares in Johnson & Johnson rise 0.6% to $148.38 on Mon ahead of quarterly results. JNJ expected to report adj EPS of $2.64, down 1.54% from a year earlier. The company's quarterly results will be released before market open on Tues.
Reuters · 04/16 09:00
BUZZ-PREVIEW: Johnson & Johnson shares rise ahead of quarterly results
Shares in Johnson & Johnson rise 0.6% to $148.38 on Mon ahead of quarterly results. JNJ expected to report adj EPS of $2.64, down 1.54% from last quarter. The company's quarterly results will be released before market open on Tues.
Reuters · 04/15 16:53
Big Pharma patent cliffs seen fueling oncology M&A this year
Big Pharma patent cliffs seen fueling oncology M&A this year. Around $182B in revenue is at risk over the next four years due to patent expirations. Cantor Fitzgerald sees between five and 17 acquisition deals for oncologists in 2014. The global market for cancer drugs is expected to grow from $180B in 2022 to $323B in 2028.
Seeking Alpha · 03/10 17:08
*News On Ambrx Biopharma Inc. (AMAM) Now Under JNJ
Dow Jones · 03/07 22:08
Ambrx Biopharma’s Landmark Merger and Corporate Overhaul
TipRanks · 03/07 14:03
Ambrx Biopharma: Vote Results and Forward-Looking Statements Warning
TipRanks · 03/06 21:26
*Ambrx Hldrs Approve Acquisition by Johnson & Johnson
Dow Jones · 03/06 18:20
Press Release: Ambrx Shareholders Approve Acquisition by Johnson & Johnson
Ambrx Shareholders Approve Acquisition by Johnson & Johnson. More than 99% of the votes cast at the Special Meeting were voted in favor of adopting the merger agreement. Ambrx shareholders will receive $28.00 per share in cash in connection with the closing of the transaction. The company expects to complete the transaction on March 7, 2024.
Dow Jones · 03/06 18:20
Weekly Report: what happened at AMAM last week (0226-0301)?
Weekly Report · 03/04 09:10
Weekly Report: what happened at AMAM last week (0219-0223)?
Weekly Report · 02/26 09:11
Ambrx Biopharma ticks higher as HSR waiting period for J&J deal expires
Ambrx Biopharma ticks higher as HSR waiting period for J&J deal expires. Johnson & Johnson (JNJ) agreed to acquire the developer of cancer drugs for $28 per share in cash last month. Ambrx's planned sale to JNJ is expected to close in 2024.
Seeking Alpha · 02/22 14:40
Ambrx Biopharma Nears Acquisition by Johnson & Johnson
Ambrx Biopharma, Inc. Is on the cusp of becoming a wholly owned subsidiary of Johnson & Johnson. Stockholders of Ambrx are scheduled to vote on the merger agreement on March 6, 2024. The merger has already cleared a regulatory hurdle.
TipRanks · 02/22 13:44
Weekly Report: what happened at AMAM last week (0212-0216)?
Weekly Report · 02/19 09:11
3 Pharma Stock Buys With Accelerating Gains
Neurocrine Biosciences, Inc. (NBIX), AstraZeneca PLC (AZN) and Johnson & Johnson (JNJ) are fundamentally strong pharma stocks. The pharmaceutical industry is expected to thrive as demand increases and technology advances. The three stocks are expected to be ideal additions to your portfolio for gains.
Barchart · 02/15 12:14
Weekly Report: what happened at AMAM last week (0205-0209)?
Weekly Report · 02/12 09:11
AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
Former Attorney General of Louisiana Charles C. Foti, Jr. And the law firm of Kahn Swick & Foti are investigating the proposed sale of Ambrx Biopharma, Inc. To Johnson & Johnson. Under the terms of the proposed transaction, shareholders will receive $28.00 in cash for each share. KSF is seeking to determine whether the consideration undervalues the Company.
Barchart · 02/10 10:23
AMAM Quantitative Stock Analysis
NASDAQ · 02/06 21:00
Weekly Report: what happened at AMAM last week (0129-0202)?
Weekly Report · 02/05 09:11
Looking Into Ambrx Biopharma's Recent Short Interest
Ambrx Biopharma's short percent of float has fallen 67.62% since its last report. The company has 1.74 million shares sold short, which is 2.93% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 01/29 13:30
Weekly Report: what happened at AMAM last week (0122-0126)?
Weekly Report · 01/29 09:11
More
Webull provides a variety of real-time AMAM stock news. You can receive the latest news about Ambrx Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About AMAM
Ambrx Biopharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its ADC targeting Human epidermal growth factor receptor 2 (HER2). It uses genetic code technology platform to discover and develop engineered precision biologics. Its genetic code technology platform allows to incorporate, in a site-specific manner, synthetic amino acids (SAA), into proteins within living cells. Its SAA incorporation technology is designed to develop a range of product candidate modality, such as modified cytokines and bispecific antibodies, and others.